Adage Capital Partners Gp, L.L.C. Syndax Pharmaceuticals Inc Transaction History

Adage Capital Partners Gp, L.L.C.

$59.7 Billion
Q3 2025

A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 3,311,963 shares of SNDX stock, worth $55 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares

3,311,963

Previous 1,432,440 131.21%

Holding current value

$55 Million

Previous $13.4 Million 279.79%

% of portfolio

0.09%

Previous 0.02%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$8.73 - $17.04 $16.4 Million - $32 Million	1,879,523 Added 131.21%	3,311,963 $51 Million
Q2 2025 Aug 14, 2025	BUY	$8.9 - $14.15 $7.13 Million - $11.3 Million	800,800 Added 126.78%	1,432,440 $13.4 Million
Q1 2025 May 15, 2025	BUY	$12.29 - $16.38 $120,441 - $160,524	9,800 Added 1.58%	631,640 $7.76 Million
Q4 2024 Feb 14, 2025	SELL	$12.52 - $21.81 $2.45 Million - $4.27 Million	-195,760 Reduced 23.94%	621,840 $8.22 Million
Q3 2024 Nov 14, 2024	SELL	$17.93 - $24.81 $760,232 - $1.05 Million	-42,400 Reduced 4.93%	817,600 $15.7 Million
Q2 2024 Aug 14, 2024	SELL	$18.82 - $23.79 $752,800 - $951,600	-40,000 Reduced 4.44%	860,000 $17.7 Million
Q4 2023 Feb 14, 2024	SELL	$11.39 - $21.67 $1.14 Million - $2.17 Million	-100,000 Reduced 10.0%	900,000 $19.4 Million
Q3 2023 Nov 14, 2023	BUY	$14.52 - $21.77 $1.09 Million - $1.63 Million	75,000 Added 8.11%	1,000,000 $14.5 Million
Q2 2023 Aug 14, 2023	BUY	$19.35 - $22.31 $2.61 Million - $3.01 Million	135,000 Added 17.09%	925,000 $19.4 Million
Q1 2023 May 15, 2023	SELL	$20.66 - $28.98 $3.1 Million - $4.35 Million	-150,000 Reduced 15.96%	790,000 $16.7 Million
Q4 2022 Feb 14, 2023	SELL	$20.64 - $26.24 $6.4 Million - $8.13 Million	-310,000 Reduced 24.8%	940,000 $23.9 Million
Q3 2022 Nov 14, 2022	BUY	$18.51 - $24.79 $235,077 - $314,833	12,700 Added 1.03%	1,250,000 $30 Million
Q2 2022 Aug 15, 2022	BUY	$13.64 - $19.48 $2.16 Million - $3.09 Million	158,659 Added 14.71%	1,237,300 $23.8 Million
Q1 2022 May 16, 2022	SELL	$14.84 - $22.15 $1.8 Million - $2.69 Million	-121,359 Reduced 10.11%	1,078,641 $18.7 Million
Q4 2021 Feb 14, 2022	SELL	$15.23 - $22.47 $25.4 Million - $37.4 Million	-1,666,272 Reduced 58.13%	1,200,000 $26.3 Million
Q3 2021 Nov 15, 2021	BUY	$13.87 - $19.8 $5.2 Million - $7.43 Million	375,000 Added 15.05%	2,866,272 $54.8 Million
Q2 2021 Aug 16, 2021	BUY	$13.42 - $25.18 $9.95 Million - $18.7 Million	741,272 Added 42.36%	2,491,272 $42.8 Million
Q1 2021 May 17, 2021	SELL	$19.28 - $24.59 $1.55 Million - $1.98 Million	-80,439 Reduced 4.39%	1,750,000 $39.1 Million
Q4 2020 Feb 16, 2021	BUY	$15.1 - $26.44 $1.97 Million - $3.45 Million	130,439 Added 7.67%	1,830,439 $40.7 Million
Q3 2020 Nov 16, 2020	BUY	$13.39 - $17.48 $8.7 Million - $11.4 Million	650,000 Added 61.9%	1,700,000 $25.1 Million
Q2 2020 Aug 14, 2020	BUY	$8.94 - $20.98 $447,000 - $1.05 Million	50,000 Added 5.0%	1,050,000 $15.6 Million
Q1 2020 May 15, 2020	SELL	$6.65 - $12.03 $1.66 Million - $3.01 Million	-250,000 Reduced 20.0%	1,000,000 $11 Million
Q3 2019 Nov 14, 2019	SELL	$7.47 - $10.76 $1.68 Million - $2.42 Million	-225,000 Reduced 15.25%	1,250,000 $9.34 Million
Q2 2019 Aug 14, 2019	SELL	$4.9 - $9.31 $367,500 - $698,250	-75,000 Reduced 4.84%	1,475,000 $13.7 Million
Q1 2019 May 15, 2019	BUY	$4.26 - $6.86 $6.6 Million - $10.6 Million	1,550,000 New	1,550,000 $8.14 Million

Others Institutions Holding SNDX

# of Institutions

254

Shares Held

99.9M

Call Options Held

1.41M

Put Options Held

737K

View Full List

About Syndax Pharmaceuticals Inc

Ticker SNDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,565,200
Market Cap $940M
Description
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...

More about SNDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.

Account

Adage Capital Partners Gp, L.L.C. Syndax Pharmaceuticals Inc Transaction History